• 00Days
  • 00Hrs
  • 00Mins
  • 00Secs

Abstracts

LATE BREAKING ABSTRACT SUBMISSIONS NOW OPEN!

Late breaking abstract submissions are available again in 2024.

Late breaking submissions open: 20 May 2024
Late breaking submissions close: 21 June 2024

NOTE: All late breaking abstracts will not be eligible for the early bird registration or journal publication. 

Before submitting your abstract, ensure you read the below guidelines carefully. All information that you require is included below.

Important note: Please ensure that you add “wearemci.com” and “aplarcongress.com” to your white list / accepted email lists. This will ensure that you receive all necessary communications from us regarding your congress participation. 

Important dates
Please diarise the following important program dates

Submissions are now closed

Late breaking submissions open: 20 May 2024

Late breaking submissions close: 21 June 2024

Notifications (standard abstracts) sent: Late June 2024

Please contact program@aplarcongress.com if you have any questions regarding your submission or the program in general.

BACK IN 2024!

In 2024, APLAR is continuing the rolling review of all abstract submissions. This means that you will be able to receive your submission result ahead of the submission deadline.

We anticipate being able to advise your preliminary submission result within 2 weeks of your submission (not before 15 April 2024).

What does this mean for you? 

  • Earlier preliminary result (full details included in notification letter) before the submission deadline!
  • Enables you to plan for your attendance earlier than ever before!
    • Apply for leave from your institution earlier
    • Complete your registration earlier
    • Apply for visa earlier (if applicable)
    • Plan your travel to Singapore earlier

Presentation formats

Abstracts can be submitted for either oral or poster presentations.

Oral presentations
Oral presentations will be asked to present an oral presentation at the congress including a PowerPoint presentation and Q&A with the audience.

Poster presentations
Poster presentations will be asked to present a traditional physical poster display.

Abstract presentation guidelines

We have prepared abstract guidelines to assist you with preparing your abstract for the congress.

It is important to read these carefully when preparing for your submission.

To read detailed information below please click on “+” buttons below.

Outlined below are the guidelines that must be followed when submitting your work to APLAR 2024. 

  • All submissions must be in English. English is the official congress language and all presentations must also be in English
  • Submission titles must not be longer than 20 words and must clearly indicate the nature of the presentation
  • Submissions must not exceed 400 words, be clear and concise, highlight relevant aspects, findings and conclusions
  • Only standard abbreviations may be used within submissions
  • References are not required for submissions
  • The abstract title, section headings and references are not included in the overall word count
  • Abstracts should follow the following format
    • Background/Purpose: background or statement of purpose
    • Methods: methods, materials and analytical procedure used
    • Results: summary of the results in sufficient detail to support conclusion (we do not recommend including “results will be discussed”)
    • Conclusion: conclusions reached
    • Tables, graphs and images are permitted within submissions (maximum 2)
  • What is an encore presentation?
    An encore presentation is one where you have already presented the submitted work before. For example if you have presented the work at another rheumatology event.
  • Does APLAR 2024 accept encore presentations?
    • Yes we do accept encore presentations
    • Encore presentations are permitted as long as work has been presented after APLAR 2023 (7 – 11 December 2023)
    • Encore presentations are permitted as long as work has not previously been published prior to submission
    • Encore submissions are required to disclose the name and date of the event where it has been presented
  • Original abstracts are strongly recommended

IMPORTANT
Please enter submission information carefully, information will be published exactly as submitted

All abstract submissions must be received online through the abstract submission portal.

  • Advances in pain management
  • Allied health: alternative medicine
  • Allied health: case report
  • Allied health: COVID-19
  • Allied health: nursing
  • Allied health: physiotherapy
  • Allied health: psychological intervention and miscellaneous forms of care
  • Antiphospholipid syndrome
  • Autoinflammatory diseases
  • Basic science related to rheumatic diseases
  • Behcet’s disease and miscellaneous rheumatic conditions
  • Big data
  • Case report
  • Clinical immunology related to rheumatic diseases
  • COVID-19
  • Crystal-induced diseases
  • Epidemiology, COPCORD, health care system and pharmacoeconomics
  • Fibromyalgia
  • Genetics
  • IgG4-related disease
  • Imaging techniques and diagnosis
  • Infection-related rheumatic diseases
  • Medical technologies and innovation (including AI)
  • Metabolic bone diseases
  • Osteoarthritis
  • Paediatric rheumatology
  • Precision medicine
  • Psoriatic arthritis
  • Rehabilitation for rheumatic diseases
  • Rheumatoid arthritis anti-TNF therapy
  • Rheumatoid arthritis bDMARDs
  • Rheumatoid arthritis clinical aspects and co-morbidity
  • Rheumatoid arthritis csDMARDs
  • Rheumatoid arthritis non biological treatment
  • Rheumatoid arthritis non-TNF biological therapies
  • Rheumatoid arthritis tsDMARDs
  • Scleroderma, myositis and related syndromes
  • Sjogren syndrome
  • Soft tissue rheumatism
  • Spondylarthropathies biological and non-biological therapies
  • Spondylarthropathies clinical aspects and co-morbidity
  • Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications
  • Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies
  • Systemic vasculitis related to rheumatic diseases
  • Telemedicine

Abstract review

  • All submitted abstracts will be peer reviewed (blind review) by a subsection of the APLAR 2024 Scientific Committee
  • Incomplete abstracts or abstracts not written in English cannot be processed and will not be reviewed
  • No revisions are possible after the submission deadline – no exceptions.

Conditions of acceptance

If accepted into the official program; the following conditions will apply:

  • Oral presentations can only be presented by one author
  • Presenters must be a listed author on the submission
  • Accepted presenters must register, pay and attend the congress, otherwise the abstract will not be included in the official program or published in the IJRD supplement
  • Abstract submissions remain the property of APLAR and the Scientific Committee reserves the right to publish and distribute

Terms and conditions

All abstract submitters are required to agree to the below terms and conditions prior to submitting their work:

  • Submitting author hereby commits with the present data protection and privacy policy
  • Submitting authors declare that the submission is the original work of at least one author/presenter
  • No funding is provided to accepted presenters. Accepted presenters acknowledge they must register, pay and attend the congress for their work to be included in the official program. 
  • Submitting authors must declare the work described in the abstract has appropriate approval under local, ethical and animal experimentation rules
  • Submitting authors must declare that their work does not conflict with any existing copyright agreements with alternate publishers
  • Submitting authors provide consent for their presentation materials to be used to assist APLAR 2024, future congresses and on-demand content

Further questions

If you have any questions regarding abstract submissions, the program or the congress as a whole, please contact the APLAR Program Manager.

BACK IN 2024!

In 2024, APLAR is continuing the rolling review of all abstract submissions. This means that you will be able to receive your submission result ahead of the submission deadline. 

We anticipate being able to advise your preliminary submission result within 2 weeks of your submission (not before 15 April 2024).

What does this mean for you? 

  • Earlier preliminary result (full details included in notification letter) before the submission deadline!
  • Enables you to plan for your attendance earlier than ever before!
    • Apply for leave from your institution earlier
    • Complete your registration earlier
    • Apply for visa earlier (if applicable)
    • Plan your travel to Singapore earlier

Abstract presentation guidelines

We have prepared abstract guidelines to assist with preparing their abstract submission for the congress.

It is important to read these carefully when preparing for your presentation. 

To read detailed information below please click on “+” buttons below.

Presentation guidelines

We have prepared guidelines to assist presenters with preparing their presentations for the congress.

It is important to read these guidelines carefully when preparing for your presentation. 

To read detailed information below please click on “+” buttons below.

Late breaking submission guidelines

Outlined below are the guidelines that must be followed when submitting a late breaking abstract submission to APLAR 2023. 

  • A late breaking abstract submission should contain new information and high-impact scientific research where results were not available at the time of the general abstract submission deadline
  • The scientific program committee will review all submitted abstracts. Notification regarding abstract acceptance and scheduling will be sent to the submitting author
  • A limited number of late breaking abstracts will be accepted for an oral presentation. Some abstracts may be offered a poster presentation instead
  • If the abstract is selected for either a poster or an oral presentation, you will not be eligible for early bird registration rates and must pay standard/late fees for the APLAR 2023 Congress
  • Late breaking abstracts must not be a revision of an abstract submitted prior to the original submission deadline
  • Late breaking abstracts must not have been presented or accepted for presentation at any other scientific meeting or published in any other journal at the time of submission
  • Late breaking science abstracts will not be published in the International Journal of Rheumatic Diseases (IJRD). They will be available online on the APLAR 2023 Congress website as a PDF after the congress
  • All general abstract submission guidelines must be followed in addition to the above points


All abstract submissions must be received online through the abstract submission portal.

Abstract submission guidelines

Outlined below are the guidelines that must be followed when submitting your work to APLAR 2023. 

 

  • All submissions must be in English. English is the official congress language and all presentations must also be in English
  • Submission titles must not be longer than 20 words and must clearly indicate the nature of the presentation
  • Submissions must not exceed 400 words, be clear and concise, highlight relevant aspects, findings and conclusions
  • Only standard abbreviations may be used within submissions
  • References are not required for submissions
  • The abstract title, section headings and references are not included in the overall word count
  • Abstracts should follow the following format
    • Background/Purpose: background or statement of purpose
    • Methods: methods, materials and analytical procedure used
    • Results: summary of the results in sufficient detail to support conclusion (we do not recommend including “results will be discussed”)
    • Conclusion: conclusions reached
    • Tables, graphs and images are permitted within submissions (maximum 2)
  • What is an encore presentation?
    An encore presentation is one where you have already presented the submitted work before. For example if you have presented the work at another rheumatology event.
  • Does APLAR 2022 accept encore presentations?
    • Yes we do accept encore presentations
    • Encore presentations are permitted as long as work has been presented after APLAR 2022 (6 – 9 December 2022)
    • Encore presentations are permitted as long as work has not previously been published prior to submission
    • Encore submissions are required to disclose the name and date of the event where it has been presented
  • Original abstracts are strongly recommended

 

IMPORTANT
Please enter submission information carefully, information will be published exactly as submitted

All abstract submissions must be received online through the abstract submission portal.

Abstract submission topics
  • Advances in pain management
  • Alternative medicine e.g. acupuncture
  • Antiphospholipid syndrome
  • Autoinflammatory diseases
  • Basic science related to rheumatic diseases
  • Behcet’s disease and miscellaneous rheumatic conditions
  • Case report
  • Clinical immunology related to rheumatic diseases
  • COVID-19
  • Crystal-induced diseases pathogenesis and risk factors
  • Crystal-induced diseases clinical manifestations, outcomes, quality of life
  • Crystal-induced diseases treatments
  • Epidemiology, COPCORD, health care system and pharmacoeconomics
  • Fibromyalgia
  • Genetics
  • Imaging techniques and diagnosis
  • Infection-related rheumatic diseases
  • Innovation in research tools i.e. big data, precision medicine
  • Innovative medical technology i.e. Artificial Intelligence / machine learning
  • Metabolic bone diseases
  • Myositis and inflammatory myopathy pathogenesis and risk factors
  • Myositis and inflammatory myopathy clinical manifestations, outcomes, quality of life
  • Myositis and inflammatory myopathy treatments
  • Osteoarthritis pathogenesis and risk factors
  • Osteoarthritis clinical manifestations, outcomes, quality of life
  • Osteoarthritis treatments
  • Osteoporosis pathogenesis and risk factors
  • Osteoporosis clinical manifestations, outcomes, quality of life
  • Osteoporosis treatments
  • Paediatric rheumatology
  • Physiotherapy
  • Psoriatic arthritis pathogenesis and risk factors
  • Psoriatic arthritis clinical manifestations, outcomes, quality of life
  • Psoriatic arthritis treatments
  • Psychological intervention and miscellaneous forms of care
  • Rehabilitation for rheumatic diseases
  • Rheumatoid arthritis pathogenesis and risk factors
  • Rheumatoid arthritis clinical manifestations, outcomes, quality of life
  • Rheumatoid arthritis conventional DMARDs
  • Rheumatoid arthritis biologic DMARDs and advance treatment
  • Scleroderma and related disorders pathogenesis and risk factors
  • Scleroderma and related disorders clinical manifestations, outcomes, quality of life
  • Scleroderma and related disorders treatments
  • Sjogren syndrome
  • Soft tissue rheumatism
  • Spondylarthropathies pathogenesis and risk factors
  • Spondylarthropathies clinical manifestations, outcomes, quality of life
  • Spondyloarthropathies conventional DMARDs
  • Spondyloarthropathies biologic DMARDs and advance treatments
  • Systemic lupus erythematosus pathogenesis and risk factors
  • Systemic lupus erythematosus clinical manifestations, outcomes, quality of life
  • Systemic lupus erythematosus treatments
  • Systemic vasculitis pathogenesis and risk factors
  • Systemic vasculitis clinical manifestations, outcomes, quality of life
  • Systemic vasculitis treatments
  • Telemedicine
Abstract submission guidelines

Outlined below are the guidelines that must be followed when submitting your work to APLAR 2024. 

  • All submissions must be in English. English is the official congress language and all presentations must also be in English
  • Submission titles must not be longer than 20 words and must clearly indicate the nature of the presentation
  • Submissions must not exceed 400 words, be clear and concise, highlight relevant aspects, findings and conclusions
  • Only standard abbreviations may be used within submissions
  • References are not required for submissions
  • The abstract title, section headings and references are not included in the overall word count
  • Abstracts should follow the following format
    • Background/Purpose: background or statement of purpose
    • Methods: methods, materials and analytical procedure used
    • Results: summary of the results in sufficient detail to support conclusion (we do not recommend including “results will be discussed”)
    • Conclusion: conclusions reached
    • Tables, graphs and images are permitted within submissions (maximum 2)
  • What is an encore presentation?
    An encore presentation is one where you have already presented the submitted work before. For example if you have presented the work at another rheumatology event.
  • Does APLAR 2024 accept encore presentations?
    • Yes we do accept encore presentations
    • Encore presentations are permitted as long as work has been presented after APLAR 2023 (7 – 11 December 2023)
    • Encore presentations are permitted as long as work has not previously been published prior to submission
    • Encore submissions are required to disclose the name and date of the event where it has been presented
  • Original abstracts are strongly recommended

IMPORTANT
Please enter submission information carefully, information will be published exactly as submitted

All abstract submissions must be received online through the abstract submission portal.

Abstract submission topics
  • Advances in pain management
  • Allied health: alternative medicine
  • Allied health: case report
  • Allied health: COVID-19
  • Allied health: nursing
  • Allied health: physiotherapy
  • Allied health: psychological intervention and miscellaneous forms of care
  • Antiphospholipid syndrome
  • Autoinflammatory diseases
  • Basic science related to rheumatic diseases
  • Behcet’s disease and miscellaneous rheumatic conditions
  • Big data
  • Case report
  • Clinical immunology related to rheumatic diseases
  • COVID-19
  • Crystal-induced diseases
  • Epidemiology, COPCORD, health care system and pharmacoeconomics
  • Fibromyalgia
  • Genetics
  • IgG4rd disease
  • Imaging techniques and diagnosis
  • Infection-related rheumatic diseases
  • Medical technologies and innovation (including AI)
  • Metabolic bone diseases
  • Osteoarthritis
  • Paediatric rheumatology
  • Precision medicine
  • Psoriatic arthritis
  • Rehabilitation for rheumatic diseases
  • Rheumatoid arthritis anti-TNF therapy
  • Rheumatoid arthritis bDMARDs
  • Rheumatoid arthritis clinical aspects and co-morbidity
  • Rheumatoid arthritis csDMARDs
  • Rheumatoid arthritis non biological treatment
  • Rheumatoid arthritis non-TNF biological therapies
  • Rheumatoid arthritis tsDMARDs
  • Scleroderma, myositis and related syndromes
  • Sjogren syndrome
  • Soft tissue rheumatism
  • Spondylarthropathies biological and non-biological therapies
  • Spondylarthropathies clinical aspects and co-morbidity
  • Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications
  • Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies
  • Systemic vasculitis related to rheumatic diseases
  • Telemedicine

Presentation formats

Abstracts can be submitted for either oral or poster presentations.

Oral presentations
Oral presentations will be asked to present an oral presentation at the congress including a PowerPoint presentation and Q&A with the audience.

Poster presentations
Poster presentations will be asked to present a traditional physical poster display.

Further questions

If you have any questions regarding abstract submissions, the program or the congress as a whole, please contact the APLAR Program Manager.

Abstract review

  • All submitted abstracts will be peer reviewed (blind review) by a subsection of the APLAR 2024 Scientific Committee
  • Incomplete abstracts or abstracts not written in English cannot be processed and will not be reviewed
  • No revisions are possible after the submission deadline – no exceptions.

Conditions of acceptance

If accepted into the official program; the following conditions will apply:

  • Oral presentations can only be presented by one author
  • Presenters must be a listed author on the submission
  • Accepted presenters must register, pay and attend the congress, otherwise the abstract will not be included in the official program or published in the IJRD supplement
  • Abstract submissions remain the property of APLAR and the Scientific Committee reserves the right to publish and distribute

Terms and conditions

All abstract submitters are required to agree to the below terms and conditions prior to submitting their work:

  • Submitting author hereby commits with the present data protection and privacy policy
  • Submitting authors declare that the submission is the original work of at least one author/presenter
  • No funding is provided to accepted presenters. Accepted presenters acknowledge they must register, pay and attend the congress for their work to be included in the official program. 
  • Submitting authors must declare the work described in the abstract has appropriate approval under local, ethical and animal experimentation rules
  • Submitting authors must declare that their work does not conflict with any existing copyright agreements with alternate publishers
  • Submitting authors provide consent for their presentation materials to be used to assist APLAR 2024, future congresses and on-demand content